Evgen Pharma Share Discussion Threads

[amaretto1] 13/1/2021 17:07

Like VAL share price today :-)

[peanut100] 13/1/2021 15:56

Am I missing something, SNG start their first patient trial (only ONE person) in phase III, up 10% capped at £334m while EVG have hopefully near 100 patients been taken their SFX-01 for months and we're siting at a mere £15m market cap. I know this comment is a bit basic but Evgen surely has to have a serious move at some point.

[moneymunch] 13/1/2021 12:51

Lol...so maybe it would have been more relevant if it had been posted yesterday, and not a a particular positive outlook on proceedings imho, anyone post anything similar on the SNG thread recently??? Gl.;-)

[timbo003] 13/1/2021 12:30

>>>MM, given that only yesterday you were commenting on the possible outcome of the DSMB review for the ongoing STAR study, some people will find it strange that you now think that a paper discussing why clinical studies are halted early for reasons of futility is irrelevant, especially when given that for most of the cases cited in the paper, the decision followed a review by the DSMB 🙄

[moneymunch] 13/1/2021 11:52

Why ask me On Target, why don't you ask those that think that SFX-01's Covid chances are slim and those that post unrelated artilces on the reasons why trials are stopped early??? Gl ;-)

[on target] 13/1/2021 11:17

How many have you got left to dump MM?

[moneymunch] 13/1/2021 11:09

"When evidence arises that the original assessment of benefit-risk to the participant is no longer favourable, or when the beneficial effect is so evident that it is unethical not to give the treatment to all the participants, then the trial may be prematurely terminated."

[timbo003] 13/1/2021 09:54

This article "A systematic survey of randomised trials that stopped early for reasons of futility" is an interesting read



I find it surprising that there does not appear to be any general rules or criteria which are applied and in some cases the criteria for stopping are often not pre-specified!

Also note that some studies are stopped early due to benefit, now wouldn't that be nice.

[moneymunch] 13/1/2021 08:30

Near term, as well as news from the DSMB on the Covid trial, disclosure and details of the collabration on the Solid Tumour target could be a game changer, with any luck....Gla holders....back to 12p plus and more today would be nice...On and UP!!!;-)

[moneymunch] 13/1/2021 07:56

It certainly seems to be a challenge in finding effective treatments for Covid, and many promising drugs have failed to live up to expectations, even those that had initial encouraging trial data, and so undoubtedly a hard nut to crack....although SFX-01's selection for Covid-19 patient trials certinly wasn't made because they thought its chances were slim.....on the contrary, SFX-01 seems to have multiple mechanisms of action on several key pathways asscociated the respiratory problems seen in Covid, that are very well documented, that suggest that SFX-01's chances of success are infact high, time will tell of course, but the greenlight from the Data and Safety Monitoring Boards assessment on the first 100 paitents recruited will be massive news.

Evgen has multiple shots on multiple targets and offers a very exciting opportunity for trasformational UPside from this ridiculously bargain low market cap. Gla ;-)

[nobbygnome] 13/1/2021 07:23

>> bocker

Completely agree. Cancer is the jewel in the crown not Covid as the chance of a successful result in the latter are slim. I want to hear about developments in the breast cancer studies and that is the news we really need.

[moneymunch] 13/1/2021 07:06

Lol....and Broccoli....Gl ;-)

[valuetracker] 12/1/2021 23:01

This moneymunch seems to know his onions!

[bocker01] 12/1/2021 21:42

Yep, not so sure about 3p Money as it’s probably a substantial discount to the value added by the Juvenescence deal alone. But a nod through and it’ll add some. To be frank though I don’t see the pneumonia trials as our biggest plus. Sad in some ways as it’s so topical. To me the big pluses are in cancer. But of course success in just one area will add huge perceived value to all others. Super!

[moneymunch] 12/1/2021 20:54

Lack of appreciation and understanding of SFX-01's therapeutic potential over multiple disease targets, currently unloved and somewhat under the radar, with the market awaiting firm positive validation of progress made towards efficacy and progress made towards commercialisation/ JV Partnerships....if the DSMB say no, then i wouldn't be surprised to see sub 3p initially, and if they say yes to to SFX-01's Covid patient trial to continue, then the change in sentiment is likely to be dramatic....disclosure of the Solid Tumour collaboration could also be a near term game changer as well...Gla :-)

[amaretto1] 12/1/2021 20:50

Article daily mail ... COVID in gut .. Odviously connected to foods ..How bad your symptoms are.Can't paste it here...It's on DDDD thread latest post.

[bocker01] 12/1/2021 19:41

Mystery to a few of us Nobby! But it’s gonna change!

[bocker01] 12/1/2021 18:57

Yep, most bios have just one iron in the fire and we are sitting on 5 or 6 real serious possibilities...

[moneymunch] 12/1/2021 18:17

The hunt for effective therapies for solid tumors has heated up in early 2021 with a string of biotechs touting big investor checks and name-brand collaborations to chase those hard-to-treat lumps. Now, with one of its candidates already in the clinic for leukemia, Mana Therapeutics is taking a new round of funding to join the fray.

On Friday, Mana unveiled a $35 million Series A financing round that will help push the Boston-area biotech’s lead candidate through a Phase I trial and could help the company secure an IND for an off-the-shelf allogeneic molecule targeting transplant-ineligible AML and solid tumors within the year.

[amaretto1] 12/1/2021 17:09

NCYT .. all good.... GDR disaster of the year ... live + learn ...Onwards + upwards EVG :-)